Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761381 · ClinicalTrials.gov registry record
OCT Angiography and NRAI in Dementia
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03761381 is a study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 20 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03761381, a study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.
Conditions Studied
Interventions
- DEVICE Optical Coherence Tomography Angiography (OCTA) Imaging
- DEVICE Noninvasive Retinal Amyloid Imaging (NRAI)
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761381
The ClinicalTrials.gov registry entry for NCT03761381 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Optical Coherence Tomography Angiography (OCTA) Imaging is the first listed.
NCT03761381 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT03761381 about?
NCT03761381 is a clinical study titled "OCT Angiography and NRAI in Dementia". The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. Detect retinal blood vessel and blood flow changes in participants with dementia. 2. Detect amyloid protein deposits in the retinas of participants with dementia.
What is the current status of trial NCT03761381?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2018-09-14. Estimated completion is 2027-12.
What conditions does trial NCT03761381 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia.
What interventions are being tested in trial NCT03761381?
The interventions under investigation include: Optical Coherence Tomography Angiography (OCTA) Imaging (DEVICE), Noninvasive Retinal Amyloid Imaging (NRAI) (DEVICE).
Who is sponsoring clinical trial NCT03761381?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03761381 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.